<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1136C7A2-DF36-47F6-9BF1-C86C0087F9B6"><gtr:id>1136C7A2-DF36-47F6-9BF1-C86C0087F9B6</gtr:id><gtr:name>FibroGen, Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1ACF2D37-682E-48E9-8C39-AECA9C57614F"><gtr:id>1ACF2D37-682E-48E9-8C39-AECA9C57614F</gtr:id><gtr:name>Immunocore Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1136C7A2-DF36-47F6-9BF1-C86C0087F9B6"><gtr:id>1136C7A2-DF36-47F6-9BF1-C86C0087F9B6</gtr:id><gtr:name>FibroGen, Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1ACF2D37-682E-48E9-8C39-AECA9C57614F"><gtr:id>1ACF2D37-682E-48E9-8C39-AECA9C57614F</gtr:id><gtr:name>Immunocore Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/76FC6962-8CDC-4ACB-96BE-F9FB63D9B0DA"><gtr:id>76FC6962-8CDC-4ACB-96BE-F9FB63D9B0DA</gtr:id><gtr:firstName>Timothy James</gtr:firstName><gtr:surname>Peters</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/83592D05-0F33-48D3-94E8-A2F67A836408"><gtr:id>83592D05-0F33-48D3-94E8-A2F67A836408</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Topley</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801676"><gtr:id>B46D1243-2927-4212-AB17-23D83A74A529</gtr:id><gtr:title>DPFS Resource Request (Cardiff University/Bristol University SARTRE):A core protein production facility</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801676</gtr:grantReference><gtr:abstractText>There is an essential need for new treatments to fight infectious and inflammatory diseases. This proposal will provide essential core facilities that will allow scientific discoveries to be more rapidly realized in clinical treatments. One of the problems in drug development is the amount of time to bring a scientific idea to the clinic. By centralizing resources across the cardiff/Bristol Alliance this should allow researches in both universities to engage in more collaboration and thereby more rapidly take ideas and realize them as novel treatments.</gtr:abstractText><gtr:technicalSummary>The current application seeks funding to support the establishment of a core protein production facility that will support the translational objectives of the Cardiff University/Bristol University Severnside strategic alliance (SARTRE). Based within the existing core facilities portfolio at cardiff University, School of Medicine (Central Biotechnology Services) this protein production facility will address a significant bottleneck in progressing protein and peptide-based therapeutics through the translational pipeline by providing medium scale rapid production (to pre-GMP standard) of high purity proteins for early and late phase proof-of-concept studies. It will thus provide a central resource across the Severnside Alliance that will underpin current and significantly facilitate the development of therapeutics and diagnostic in our identified areas of research excellence.</gtr:technicalSummary><gtr:fund><gtr:end>2011-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>416908</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Recombinant synthesis and purification of discrete human cardiac ryanodine receptor (RyR) domains</gtr:description><gtr:id>4B118CFA-FE35-4492-B7C5-9C971712E013</gtr:id><gtr:impact>See publications</gtr:impact><gtr:outcomeId>HLcvbcejzgz-1</gtr:outcomeId><gtr:partnerContribution>Development of new methods and scientific outputs.</gtr:partnerContribution><gtr:piContribution>Development of protein production and expression methods.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Expression of Casein Kinase i epsilon delta-C-terminus</gtr:description><gtr:id>01FA6302-420D-4ED1-A920-3EC4A3334CA4</gtr:id><gtr:impact>None to date, ongoing work</gtr:impact><gtr:outcomeId>BLP1SYjTNGi-1</gtr:outcomeId><gtr:partnerContribution>Beginning of a collaboration that should eventually use the DPFS PPF to produce proteins</gtr:partnerContribution><gtr:piContribution>DPFS PPF is working up methods for purification and production of GLP grade proteins.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Production of soluble pMHCI for crystallographic, biophysical and cellular studies.</gtr:description><gtr:id>BE9A2517-5E81-4653-A1D0-9A7591CA8C14</gtr:id><gtr:impact>Commercial work, none to date.</gtr:impact><gtr:outcomeId>HfHNurSeJFp-1</gtr:outcomeId><gtr:partnerContribution>Development of methods for protein purification.Established methods for purification of MHCI molecules.</gtr:partnerContribution><gtr:piContribution>New methods.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Production of soluble pMHCI for crystallographic, biophysical and cellular studies.</gtr:description><gtr:id>A01FC682-9BA3-4369-B848-02CED5CC48AF</gtr:id><gtr:impact>Commercial work, none to date.</gtr:impact><gtr:outcomeId>HfHNurSeJFp-2</gtr:outcomeId><gtr:partnerContribution>Development of methods for protein purification.Established methods for purification of MHCI molecules.</gtr:partnerContribution><gtr:piContribution>New methods.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>Cleavable prodrugs for therapy of complement-mediated diseases</gtr:description><gtr:id>2FA48571-D77C-46DA-BEE5-CD55E2769677</gtr:id><gtr:impact>None to date. Application for funding submitted.</gtr:impact><gtr:outcomeId>VJkoWXytC5L-1</gtr:outcomeId><gtr:partnerContribution>Development of methods for protein expression and assay development.</gtr:partnerContribution><gtr:piContribution>Development of methods.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immunocore Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The identification of biologically important peptides in a low-PH MHC eluate.</gtr:description><gtr:id>F1BF9806-E990-4333-A44C-7CA351CBCCD4</gtr:id><gtr:impact>Confidential methods.</gtr:impact><gtr:outcomeId>mG1riatPbr2-1</gtr:outcomeId><gtr:partnerContribution>Everything other than the above</gtr:partnerContribution><gtr:piContribution>Contract Research and peptide purification.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>The purification of the transmembrane domain from Ryanodine receptor</gtr:description><gtr:id>97289770-365F-4FC0-882E-47FDFF81B30C</gtr:id><gtr:impact>see publications</gtr:impact><gtr:outcomeId>ioTVmzVmVc6-1</gtr:outcomeId><gtr:partnerContribution>New methods development.</gtr:partnerContribution><gtr:piContribution>Development of methods for protein purification.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences</gtr:department><gtr:description>Small molecule antagonists at the TrkA receptor for the treatment of pain</gtr:description><gtr:id>2ECB5CB4-22F7-446D-9A91-B2CBC0032FE3</gtr:id><gtr:impact>This project is in partnering discussion with a major pharmaceutical company. New IP is being filed for patent at Bristol University.</gtr:impact><gtr:outcomeId>cPSAWFYM4Xi-1</gtr:outcomeId><gtr:partnerContribution>Proteins manufactured for X-ray crystallography of DS domain of TRKA receptor to support a SARTRE devolved DPFS project.</gtr:partnerContribution><gtr:piContribution>Developments of new methods for protein purification and production</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>FibroGen, Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Reticulocyte enrichment</gtr:description><gtr:id>251DB397-0E19-4DCD-A277-4F6F7DC8C5E1</gtr:id><gtr:impact>None, Subject to confidentiality agreement.</gtr:impact><gtr:outcomeId>GrPCLSeZavS-1</gtr:outcomeId><gtr:partnerContribution>Everything other than the above</gtr:partnerContribution><gtr:piContribution>Contract research and methods development.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meetings with potential commercial clients</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EB71D6CB-9934-4307-B14C-D40C49DABCDA</gtr:id><gtr:impact>Meeting with small groups to discuss potential contract research.

Contracts with Immunocore and FibroGen arose from these presentations/discussions.</gtr:impact><gtr:outcomeId>Ca4G79LRt5u</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>14998</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A feasibility study into Central Biotechnology Services (CBS) becoming an accredited Knowledge Transfer Centre</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>Health and Care Research Wales</gtr:fundingOrg><gtr:id>ECDB093D-D9F6-4702-AD37-7D54FE0950CD</gtr:id><gtr:outcomeId>HBaWhvu8vGJ0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Core Facilities</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A30F0A53-9D41-468B-8D4C-8B4B97A29AFB</gtr:id><gtr:outcomeId>F8C0735CEAB</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The facility has allowed us to develop improved and quality controlled methods for protein production and expression for a range of prokaryotic and eukaryotic systems.</gtr:description><gtr:id>4B782CF2-0433-4E90-B102-DF50A7822058</gtr:id><gtr:impact>Availability of proteins for follow on studies.
Widening of user base with the availability of this resource.</gtr:impact><gtr:outcomeId>2EBBCF6A9AC</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Protein Production Methods</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FD660EC2-0B05-402D-9CB1-5B42D79E5662</gtr:id><gtr:title>Male infertility-linked point mutation disrupts the Ca2+ oscillation-inducing and PIP(2) hydrolysis activity of sperm PLC?.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70e5606f53b56fc3871d611ac1832867"><gtr:id>70e5606f53b56fc3871d611ac1832867</gtr:id><gtr:otherNames>Nomikos M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>jdjE8zbgnyU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC7F8A98-091A-441F-87E5-17F06BEAD09D</gtr:id><gtr:title>Divergent effect of mammalian PLC? in generating Ca&amp;sup2;? oscillations in somatic cells compared with eggs.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80c10e2bac6a0f3c68061c9e7e62739a"><gtr:id>80c10e2bac6a0f3c68061c9e7e62739a</gtr:id><gtr:otherNames>Phillips SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>GD7YHJyum2T</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801676</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>